We are excited to share that Ali Pashazadeh, Treehill Partners CEO, was quoted in Newsweek‘s coverage of the Trump administration’s new TrumpRx prescription drug initiative — reaching an audience of over 100 million monthly readers.
The TrumpRx Initiative
The White House announced TrumpRx, a new direct-to-consumer website launching in 2026 that will allow Americans to purchase prescription drugs at significantly reduced prices. Pfizer became the first pharmaceutical company to participate, committing to discounts ranging from 40% to 85% on select medications.
Our Commentary
Drawing from Dr Pashazadeh’s deep expertise in healthcare policy and pharmaceutical economics, he provided critical analysis on the initiative’s implementation challenges, as featured in Newsweek and The American Journal of Managed Care:
On lessons from international models: reviewed challenges other countries have faced with similar pricing models, including the UK’s “brain drain” of scientists to countries with better pricing structures, and Switzerland’s decline as a biotech innovation hub.
On the core issue: discussed the logic of initiative and the government’s desire to get drugs to patients at price parity comparable to other countries; and highlighted the importance of thoughtful implementation and timing thereof.
Industry Context
Industry analysts have warned that the plan risks acting as a blunt instrument rather than a workable solution, with the initiative expected to face legal challenges. The American Journal of Managed Care noted that a similar effort during Trump’s first term was blocked in court.
Dr Pashazadeh’s balanced perspective — acknowledging the policy’s intent while highlighting critical implementation requirements — reflects Treehill Partners’ thoughtful approach to navigating complex healthcare policy and market dynamics.
About the Coverage: This marks a major article featuring Dr Pashazadeh in the largest audience reached to date through a single publication.
Read the publication: https://www.newsweek.com/donald-trump-rx-pfizer-white-house-medicine-10805621